Skip to main content

Veracyte Announces Third Quarter 2024 Financial Results

Grew total revenue to $115.9 million, an increase of 29%

Grew testing revenue to $109.5 million, an increase of 34%

Conference call and webcast today at 4:30 p.m. ET

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024.

"The strong momentum across our testing business continued during the third quarter as we delivered record revenue along with profitability and cash generation,” said Marc Stapley, Veracyte’s chief executive officer. “Looking ahead, we see tremendous opportunities for further market penetration for both Decipher and Afirma, to serve even more patients and their physicians. We also remain excited about our focused portfolio of strategic growth drivers. The Veracyte Diagnostics Platform is generating the data, insights and evidence to drive commercial success and sustained long-term growth.”

Key Financial Highlights

  • Increased third quarter total revenue by 29%, to $115.9 million, and total volume by 20%, to 39,032 tests, compared to the third quarter of 2023.
  • Increased testing revenue by 34%, to $109.5 million, and testing volume by 24%, to 36,792 tests, compared to the third quarter of 2023.
  • Grew Decipher revenue by 48% and volume by 36%, to approximately 21,250 tests, compared to the third quarter of 2023.
  • Grew Afirma revenue by 19% and volume by 12%, to close to 15,100 tests, compared to the third quarter of 2023.
  • Increased third quarter net income to $15.2 million and delivered adjusted EBITDA of $27.3 million, or 24% of revenue.
  • Generated $30.0 million of cash from operations during the third quarter to end the quarter with $274.1 million of cash and cash equivalents.

Key Business Highlights

  • Expanded clinical evidence for Decipher Prostate with a presentation at the European Society for Medical Oncology (ESMO) 2024 Congress on new data from the STAMPEDE trial, a multi-center, randomized, phase 3 clinical trial showing that the test was prognostic for clinical outcomes and predicted benefit from docetaxel in patients with metastatic prostate cancer.
  • Demonstrated Veracyte’s commitment to expanding clinical evidence in populations disproportionately impacted by prostate cancer with data from the VANDAAM study shared at ASTRO 2024, the annual meeting of the American Society for Radiation Oncology, demonstrating that Decipher Prostate accurately predicts aggressive prostate cancer among African-American men with early-stage disease.
  • Promoted Keith Gligorich Ph.D. to Senior Vice President of Global Operations and a member of the executive leadership team.
  • Appointed Tom Miller, Ph.D., and Brent Shafer to our Board of Directors.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."

Third Quarter 2024 Financial Results

Total revenue for the third quarter of 2024 was $115.9 million, an increase of 29% compared to $90.1 million reported in the third quarter of 2023. Testing revenue was $109.5 million, an increase of 34% compared to $82.0 million in the third quarter of 2023, driven by the strong performance of our Decipher Prostate and Afirma tests. Product revenue was $3.2 million, a decrease of 21% compared to $4.0 million in the third quarter of 2023. Biopharmaceutical and other revenue was $3.1 million, a decrease of 23% compared to $4.1 million in the third quarter of 2023.

Total gross margin for the third quarter of 2024 was 68%, compared to 64% in the third quarter of 2023. Non-GAAP gross margin was 71%, compared to 70% in the third quarter of 2023.

Operating expenses were $67.0 million for the third quarter of 2024. Non-GAAP operating expenses grew 11% to $57.6 million compared to $51.8 million in the third quarter of 2023.

Net income for the third quarter of 2024 was $15.2 million, an improvement of 151% compared to the third quarter of 2023. Diluted net earnings per common share was $0.19, an improvement of $0.60 compared to the third quarter of 2023. Non-GAAP diluted net earnings per common share was $0.33, an improvement of $0.16 compared to the third quarter of 2023. Net cash provided by operating activities in the first nine months of 2024 was $50.6 million, an improvement of $21.9 million compared to the same period in 2023.

Adjusted EBITDA for the third quarter of 2024 was $27.3 million, an improvement of 117% compared to the third quarter of 2023, representing 24% of revenue compared to 14% of revenue in the same period of 2023.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."

2024 Financial Outlook

The company is raising full-year 2024 total revenue guidance to $442 million to $445 million, representing year-over-year growth of 22% to 23% and testing revenue growth of approximately 28%. This guidance range represents an increase compared to prior guidance of $432 million to $438 million. In addition, the company now expects cash, cash equivalents and short-term investments at the end of the year to be $280 million to $285 million compared to prior guidance of $260 million to $270 million.

Conference Call and Webcast Details

Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/kzh3s376. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call dial-in can be accessed by registering at the following link: https://register.vevent.com/register/BI945e651d9e5f40acbfaec616e1b85b4e

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to 2024 financial and operating results; and our intentions with respect to our tests and products, for use in diagnosing and treating diseases, in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to the C2i Genomics acquisition, integration of the business and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies and our facilities in France; the impact of foreign currency fluctuations, increasing interest rates, inflation, the U.S. election and turmoil in the global banking and finance system; the ongoing conflict in the Middle East and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 29, 2024, and our Quarterly Report on Form 10-Q filed for the three months ended September 30, 2024, to be filed on November 7, 2024, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, Decipher, C2i Genomics, and Afirma are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

Note Regarding Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non‐GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA and non-GAAP earnings per share (EPS). These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies.

We exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, all stock-based compensation and certain costs related to restructuring from our non-GAAP financial measures. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from our prior period non-GAAP financial measures. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business.

 

VERACYTE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2024

 

 

2023

 

 

 

2024

 

 

2023

 

Revenue:

 

 

 

 

 

 

 

Testing revenue

$

109,536

 

$

82,012

 

 

$

306,809

 

$

236,157

 

Product revenue

 

3,188

 

 

4,020

 

 

 

10,631

 

 

11,923

 

Biopharmaceutical and other revenue

 

3,136

 

 

4,076

 

 

 

9,692

 

 

14,772

 

Total revenue

 

115,860

 

 

90,108

 

 

 

327,132

 

 

262,852

 

 

 

 

 

 

 

 

 

Cost of revenue: (1)

 

 

 

 

 

 

 

Cost of testing revenue

 

29,029

 

 

21,827

 

 

 

82,928

 

 

64,808

 

Cost of product revenue

 

1,792

 

 

2,436

 

 

 

6,310

 

 

6,913

 

Cost of biopharmaceutical and other revenue

 

3,112

 

 

3,347

 

 

 

9,762

 

 

11,806

 

Intangible asset amortization - cost of revenue

 

2,917

 

 

4,811

 

 

 

8,741

 

 

14,429

 

Total cost of revenue

 

36,850

 

 

32,421

 

 

 

107,741

 

 

97,956

 

Gross profit

 

79,010

 

 

57,687

 

 

 

219,391

 

 

164,896

 

Operating expenses: (1)

 

 

 

 

 

 

 

Research and development

 

17,574

 

 

13,322

 

 

 

50,004

 

 

38,632

 

Selling and marketing

 

22,612

 

 

24,344

 

 

 

70,610

 

 

76,230

 

General and administrative

 

25,742

 

 

16,334

 

 

 

83,697

 

 

62,434

 

Impairment of long-lived assets

 

185

 

 

34,900

 

 

 

614

 

 

36,310

 

Intangible asset amortization - operating expenses

 

880

 

 

526

 

 

 

2,499

 

 

1,578

 

Total operating expenses

 

66,993

 

 

89,426

 

 

 

207,424

 

 

215,184

 

Income (loss) from operations

 

12,017

 

 

(31,739

)

 

 

11,967

 

 

(50,288

)

Other income, net

 

4,831

 

 

1,967

 

 

 

10,334

 

 

4,148

 

Income (loss) before income taxes

 

16,848

 

 

(29,772

)

 

 

22,301

 

 

(46,140

)

Income tax provision (benefit)

 

1,693

 

 

(154

)

 

 

3,276

 

 

(29

)

Net income (loss)

$

15,155

 

$

(29,618

)

 

$

19,025

 

$

(46,111

)

Earnings (loss) per share:

 

 

 

 

 

 

 

Basic

$

0.20

 

$

(0.41

)

 

$

0.25

 

$

(0.64

)

Diluted

$

0.19

 

$

(0.41

)

 

$

0.25

 

$

(0.64

)

Shares used to compute earnings (loss) per common share:

 

 

 

 

 

 

 

Basic

 

77,013,831

 

 

72,804,770

 

 

 

76,107,302

 

 

72,488,601

 

Diluted

 

78,464,654

 

 

72,804,770

 

 

 

77,339,897

 

 

72,488,601

 

1.

Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

Cost of revenue

$

587

 

$

502

 

$

1,678

 

$

1,386

Research and development

 

1,957

 

 

1,135

 

 

5,615

 

 

3,831

Selling and marketing

 

1,790

 

 

2,521

 

 

5,025

 

 

7,126

General and administrative

 

4,413

 

 

3,174

 

 

14,302

 

 

13,539

Total stock-based compensation expense

$

8,747

 

$

7,332

 

$

26,620

 

$

25,882

 

 

VERACYTE, INC.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2024

 

 

2023

 

 

 

2024

 

 

2023

 

Net income (loss)

$

15,155

 

$

(29,618

)

 

$

19,025

 

$

(46,111

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

Change in currency translation adjustments

 

9,328

 

 

(6,414

)

 

 

2,736

 

 

(2,851

)

 

 

 

 

 

 

 

 

Net comprehensive income (loss)

$

24,483

 

$

(36,032

)

 

$

21,761

 

$

(48,962

)

 

 

VERACYTE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

 

 

 

 

 

September 30,

 

December 31,

 

 

2024

 

 

2023

 

(Unaudited)

 

(See Note 1)

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

274,079

 

$

216,454

Accounts receivable

 

48,807

 

 

40,378

Supplies and inventory

 

20,364

 

 

16,128

Prepaid expenses and other current assets

 

13,604

 

 

12,661

Total current assets

 

356,854

 

 

285,621

Property, plant and equipment, net

 

21,194

 

 

20,584

Right-of-use assets, operating leases

 

17,031

 

 

10,277

Intangible assets, net

 

108,873

 

 

88,593

Goodwill

 

762,117

 

 

702,984

Restricted cash

 

1,080

 

 

876

Other assets

 

7,872

 

 

5,971

Total assets

$

1,275,021

 

$

1,114,906

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

9,670

 

$

12,943

Accrued liabilities

 

43,872

 

 

38,427

Current portion of deferred revenue

 

2,033

 

 

2,008

Current portion of acquisition-related contingent consideration

 

7,391

 

 

2,657

Current portion of operating lease liabilities

 

7,294

 

 

5,105

Current portion of other liabilities

 

53

 

 

101

Total current liabilities

 

70,313

 

 

61,241

Deferred tax liabilities

 

1,470

 

 

734

Acquisition-related contingent consideration, net of current portion

 

14,225

 

 

518

Operating lease liabilities, net of current portion

 

12,400

 

 

7,525

Other liabilities

 

571

 

 

786

Total liabilities

 

98,979

 

 

70,804

Total stockholders’ equity

 

1,176,042

 

 

1,044,102

Total liabilities and stockholders’ equity

$

1,275,021

 

$

1,114,906

 

 

 

 

1. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited financial statements at that date included in the Company's Form 10-K filed with the Securities and Exchange Commission dated February 29, 2024.

 

 

 

VERACYTE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

 

 

 

Nine Months Ended

September 30,

 

 

2024

 

 

 

2023

 

Operating activities

 

 

 

Net income (loss)

$

19,025

 

 

$

(46,111

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

17,206

 

 

 

20,852

 

Loss on disposal of property, plant and equipment

 

131

 

 

 

136

 

Stock-based compensation

 

26,620

 

 

 

25,629

 

Deferred income taxes

 

10

 

 

 

(843

)

Noncash lease expense

 

3,628

 

 

 

3,130

 

Revaluation of acquisition-related contingent consideration

 

1,242

 

 

 

(5,500

)

Effect of foreign currency on operations

 

(785

)

 

 

657

 

Impairment loss

 

614

 

 

 

36,310

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

(8,396

)

 

 

4,650

 

Supplies and inventory

 

(4,175

)

 

 

(1,636

)

Prepaid expenses and other current assets

 

149

 

 

 

(1,578

)

Other assets

 

(1,710

)

 

 

(586

)

Operating lease liabilities

 

(3,929

)

 

 

(3,225

)

Accounts payable

 

(2,950

)

 

 

185

 

Accrued liabilities and deferred revenue

 

3,892

 

 

 

(3,400

)

Net cash provided by operating activities

 

50,572

 

 

 

28,670

 

Investing activities

 

 

 

Acquisition of C2i, net of cash acquired

 

5,012

 

 

 

 

Purchase of short-term investments

 

 

 

 

(19,700

)

Proceeds from sale of short-term investments

 

 

 

 

39,773

 

Proceeds from maturity of short-term investments

 

 

 

 

5,000

 

Purchases of property, plant and equipment

 

(7,146

)

 

 

(7,464

)

Net cash (used in) provided by investing activities

 

(2,134

)

 

 

17,609

 

Financing activities

 

 

 

Payment of taxes on vested restricted stock units

 

(7,315

)

 

 

(5,614

)

Proceeds from the exercise of common stock options and employee stock purchases

 

16,729

 

 

 

7,806

 

Net cash provided by financing activities

 

9,414

 

 

 

2,192

 

Increase in cash, cash equivalents and restricted cash

 

57,852

 

 

 

48,471

 

Effect of foreign currency on cash, cash equivalents and restricted cash

 

(23

)

 

 

(134

)

Net increase in cash, cash equivalents and restricted cash

 

57,829

 

 

 

48,337

 

Cash, cash equivalents and restricted cash at beginning of period

 

217,330

 

 

 

154,996

 

Cash, cash equivalents and restricted cash at end of period

$

275,159

 

 

$

203,333

 

 

 

 

 

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH

(Unaudited)

(In thousands)

 

 

 

 

 

September 30,

 

December 31,

 

 

2024

 

 

2023

Cash and cash equivalents

$

274,079

 

$

216,454

Restricted cash

 

1,080

 

 

876

Total cash, cash equivalents and restricted cash

$

275,159

 

$

217,330

 

 

VERACYTE, INC.

RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES

(Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Reconciliation of Non-GAAP Cost of Revenue:

 

 

 

 

 

 

 

GAAP cost of testing revenue

$

29,029

 

 

$

21,827

 

 

$

82,928

 

 

$

64,808

 

Stock-based compensation expense

 

(524

)

 

 

(382

)

 

 

(1,411

)

 

 

(1,048

)

Acquisition related expenses (1)

 

 

 

 

 

 

 

(60

)

 

 

(74

)

Other adjustments (2)

 

 

 

 

 

 

 

(6

)

 

 

 

Non-GAAP cost of testing revenue

$

28,505

 

 

$

21,445

 

 

$

81,451

 

 

$

63,686

 

 

 

 

 

 

 

 

 

GAAP cost of product revenue

 

1,792

 

 

 

2,436

 

 

 

6,310

 

 

 

6,913

 

Stock-based compensation expense

 

(1

)

 

 

 

 

 

(3

)

 

 

 

Acquisition related expenses (1)

 

 

 

 

 

 

 

 

 

 

 

Other adjustments (2)

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP cost of product revenue

$

1,791

 

 

$

2,436

 

 

$

6,307

 

 

$

6,913

 

 

 

 

 

 

 

 

 

GAAP cost of biopharmaceutical and other revenue

 

3,112

 

 

 

3,347

 

 

 

9,762

 

 

 

11,806

 

Stock-based compensation expense

 

(62

)

 

 

(120

)

 

 

(264

)

 

 

(337

)

Acquisition related expenses (1)

 

 

 

 

 

 

 

 

 

 

 

Other adjustments (2)

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP cost of biopharmaceutical and other revenue

$

3,050

 

 

$

3,227

 

 

$

9,498

 

 

$

11,469

 

 

 

 

 

 

 

 

 

Reconciliation of Non-GAAP Gross Margin:

 

 

 

 

 

 

 

GAAP Gross Profit

$

79,010

 

 

$

57,687

 

 

$

219,391

 

 

$

164,896

 

GAAP Gross Margin

 

68

%

 

 

64

%

 

 

67

%

 

 

63

%

Amortization of intangible assets

 

2,917

 

 

 

4,811

 

 

 

8,741

 

 

 

14,429

 

Stock-based compensation expense

 

587

 

 

 

502

 

 

 

1,678

 

 

 

1,385

 

Acquisition related expenses (1)

 

 

 

 

 

 

 

60

 

 

 

74

 

Other adjustments (2)

 

 

 

 

 

 

 

6

 

 

 

 

Non-GAAP Gross Profit

$

82,514

 

 

$

63,000

 

 

$

229,876

 

 

$

180,784

 

Non-GAAP Gross Margin

 

71

%

 

 

70

%

 

 

70

%

 

 

69

%

 

 

 

 

 

 

 

 

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the nine months ended September 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics. For the nine months ended September 30, 2023, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HalioDx.

2. For the nine months ended September 30, 2024, adjustments include expense related to restructuring costs associated with portfolio prioritization.

 

VERACYTE, INC.

RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES

(Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Reconciliation of Non-GAAP Operating Expenses:

 

 

 

 

 

 

 

GAAP research and development

$

17,574

 

 

$

13,322

 

 

$

50,004

 

 

$

38,632

 

Stock-based compensation expense

 

(1,957

)

 

 

(1,135

)

 

 

(5,615

)

 

 

(3,831

)

Acquisition related expenses (1)

 

459

 

 

 

 

 

 

62

 

 

 

 

Other adjustments (2)

 

5

 

 

 

 

 

 

(271

)

 

 

 

Non-GAAP research and development

$

16,081

 

 

$

12,187

 

 

$

44,180

 

 

$

34,801

 

 

 

 

 

 

 

 

 

GAAP sales and marketing

$

22,612

 

 

$

24,344

 

 

$

70,610

 

 

$

76,230

 

Stock-based compensation expense

 

(1,790

)

 

 

(2,521

)

 

 

(5,025

)

 

 

(7,126

)

Acquisition related expenses (1)

 

 

 

 

(209

)

 

 

(124

)

 

 

(1,366

)

Other adjustments (2)

7

(1,087

)

Non-GAAP sales and marketing

$

20,829

 

 

$

21,614

 

 

$

64,374

 

 

$

67,738

 

 

 

 

 

 

 

 

 

GAAP general and administrative

$

25,742

 

 

$

16,334

 

 

$

83,697

 

 

$

62,434

 

Stock-based compensation expense

 

(4,413

)

 

 

(3,174

)

 

 

(14,302

)

 

 

(13,539

)

Acquisition related expenses (1)

 

(349

)

 

 

4,790

 

 

 

(4,934

)

 

 

3,165

 

Other adjustments (2)

 

(248

)

 

 

 

 

 

(3,368

)

 

 

66

 

Non-GAAP general and administrative

$

20,732

 

 

$

17,950

 

 

$

61,093

 

 

$

52,126

 

 

 

 

 

 

 

 

 

GAAP total operating expenses

$

66,993

 

 

$

89,426

 

 

$

207,424

 

 

$

215,184

 

Amortization of intangible assets

 

(880

)

 

 

(526

)

 

 

(2,499

)

 

 

(1,578

)

Stock-based compensation expense

 

(8,160

)

 

 

(6,830

)

 

 

(24,942

)

 

 

(24,496

)

Acquisition related expenses (1)

 

(75

)

 

 

4,581

 

 

 

(5,610

)

 

 

1,799

 

Other adjustments (2)

 

(236

)

 

 

(34,900

)

 

 

(4,726

)

 

 

(36,244

)

Non-GAAP total operating expenses

$

57,642

 

 

$

51,751

 

 

$

169,647

 

 

$

154,665

 

 

 

 

 

 

 

 

 

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics ($0.1 million). For the three months ended September 30, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HalioDx. For the nine months ended September 30, 2024, adjustments consist of transaction related expenses associated with the acquisition of C2i Genomics. For the nine months ended September 30, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HalioDx.

2. For the three months ended September 30, 2024, adjustments primarily include expense related to restructuring costs ($0.2 million). For the three months ended September 30, 2023, adjustments include $34.9 million expense related to nCounter license impairment related to our adoption of a multi-platform IVD strategy. For the nine months ended September 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment ($3.1 million) and expense related to restructuring costs associated with portfolio prioritization including the reduction in Envisia commercial support ($1.6 million). For the nine months ended September 30, 2023, adjustments primarily include $34.9 million expense related to the impairment charge associated with the nCounter license intangible assets and $1.3 million related to other impairment charges.

 

VERACYTE, INC.

RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES

(Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Reconciliation of Adjusted EBITDA:

 

 

 

 

 

 

 

GAAP Net Income (Loss)

$

15,155

 

 

$

(29,618

)

 

$

19,025

 

 

$

(46,111

)

Amortization of intangible assets

 

3,797

 

 

 

5,337

 

 

 

11,240

 

 

 

16,007

 

Depreciation expense

 

2,081

 

 

 

1,985

 

 

 

5,966

 

 

 

4,845

 

Stock-based compensation expense

 

8,747

 

 

 

7,332

 

 

 

26,620

 

 

 

25,882

 

Acquisition related expenses (1)

 

75

 

 

 

(4,581

)

 

 

5,670

 

 

 

(1,725

)

Other expense (income), net (2)

 

(3,366

)

 

 

(2,620

)

 

 

(9,679

)

 

 

(4,523

)

Other adjustments (3)

 

(853

)

 

 

34,900

 

 

 

3,643

 

 

 

36,244

 

Income tax expense (benefit)

 

1,693

 

 

 

(154

)

 

 

3,276

 

 

 

(29

)

Adjusted EBITDA

$

27,329

 

 

$

12,581

 

 

$

65,761

 

 

$

30,590

 

 

 

 

 

 

 

 

 

Reconciliation of Non-GAAP Net Income (Loss)

 

 

 

 

 

 

 

GAAP Net Income (Loss)

$

15,155

 

 

$

(29,618

)

 

$

19,025

 

 

$

(46,111

)

Amortization of intangible assets

 

3,797

 

 

 

5,337

 

 

 

11,240

 

 

 

16,007

 

Stock-based compensation expense

 

8,747

 

 

 

7,332

 

 

 

26,620

 

 

 

25,882

 

Acquisition related expenses (1)

 

75

 

 

 

(4,581

)

 

 

5,670

 

 

 

(1,725

)

Other adjustments (3)

 

(853

)

 

 

34,900

 

 

 

3,643

 

 

 

36,244

 

Tax adjustments (4)

 

(933

)

 

 

(1,124

)

 

 

(2,179

)

 

 

(2,251

)

Non-GAAP Net Income

$

25,988

 

 

$

12,246

 

 

$

64,019

 

 

$

28,046

 

 

 

 

 

 

 

 

 

Reconciliation of Non-GAAP Earnings per Share

 

 

 

 

 

 

 

Diluted earnings per share, GAAP

$

0.19

 

 

$

(0.41

)

 

$

0.25

 

 

$

(0.64

)

Amortization of intangible assets

 

0.05

 

 

 

0.07

 

 

 

0.15

 

 

 

0.22

 

Stock-based compensation expense

 

0.11

 

 

 

0.10

 

 

 

0.34

 

 

 

0.36

 

Acquisition related expenses (1)

 

 

 

 

(0.06

)

 

 

0.07

 

 

 

(0.02

)

Other adjustments (3)

 

(0.01

)

 

 

0.48

 

 

 

0.05

 

 

 

0.50

 

Tax adjustments (4)

 

(0.01

)

 

 

(0.02

)

 

 

(0.03

)

 

 

(0.03

)

Rounding and impact of dilutive shares

 

 

 

 

0.01

 

 

 

 

 

 

(0.01

)

Diluted earnings per share, non-GAAP

$

0.33

 

 

$

0.17

 

 

$

0.83

 

 

$

0.38

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding used in computing diluted earnings per share

 

 

 

 

 

 

 

Diluted, GAAP

 

78,464,654

 

 

 

72,804,770

 

 

 

77,339,897

 

 

 

72,488,601

 

Dilutive effect of equity awards (5)

 

 

 

 

1,326,143

 

 

 

 

 

 

1,387,582

 

Diluted, non-GAAP

 

78,464,654

 

 

 

74,130,913

 

 

 

77,339,897

 

 

 

73,876,183

 

 

 

 

 

 

 

 

 

1. Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2024, adjustments consist primarily of transaction related expenses associated with the acquisition of C2i Genomics ($0.1 million). For the three months ended September 30, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HalioDx. For the nine months ended September 30, 2024, adjustments consist of transaction related expenses associated with the acquisition of C2i Genomics. For the nine months ended September 30, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HalioDx.

2. Includes interest income and income related to research tax credits.

3. For the three months ended September 30, 2024, adjustments include the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($1.1 million) partially offset by expense related to restructuring costs ($0.2 million). For the three months ended September 30, 2023, adjustments include $34.9 million expense related to nCounter license impairment related to our adoption of a multi-platform IVD strategy. For the nine months ended September 30, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other Segment ($3.1 million) and expense related to restructuring costs associated with portfolio prioritization including the reduction in Envisia commercial support ($1.6 million), partially offset by the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($1.1 million). For the nine months ended September 30, 2023, adjustments primarily include $34.9 million expense related to the impairment charge associated with the nCounter license intangible assets and $1.3 million related to other impairment charges.

4. Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed.

5. In those periods in which GAAP net (loss) income is negative and non-GAAP net (loss) income is positive, non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method.

 

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.